Abstract | PURPOSE: CASE: RESULTS: The central retinal thickness prior to the treatment was 458 mum. After the first intravitreal injection of bevacizumab, the retinal thickness at the centre of the fovea was reduced to 322 mum. After the third injection, the central retinal thickness was 359 mum and 18 months after presentation, it reduced to 334 mum. The BCVA increased to 3/10 after the intravitreal injections of bevacizumab and remained stable during the follow-up period. The intraocular pressure was within normal range during the follow-up period. CONCLUSION:
|
Authors | Eleni Loukianou, Dimitrios Brouzas, Eleni Georgopoulou, Chrysanthi Koutsandrea, Michael Apostolopoulos |
Journal | Therapeutics and clinical risk management
(Ther Clin Risk Manag)
Vol. 6
Pg. 249-52
(May 25 2010)
ISSN: 1178-203X [Electronic] New Zealand |
PMID | 20526443
(Publication Type: Case Reports)
|